277 related articles for article (PubMed ID: 25272957)
1. Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial.
Thomaidis T; Maderer A; Formentini A; Bauer S; Trautmann M; Schwarz M; Neumann W; Kittner JM; Schad A; Link KH; Rey JW; Weinmann A; Hoffman A; Galle PR; Kornmann M; Moehler M
J Exp Clin Cancer Res; 2014 Oct; 33(1):83. PubMed ID: 25272957
[TBL] [Abstract][Full Text] [Related]
2. Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
Stahler A; Heinemann V; Giessen-Jung C; Crispin A; Schalhorn A; Stintzing S; Fischer von Weikersthal L; Vehling-Kaiser U; Stauch M; Quietzsch D; Held S; von Einem JC; Holch J; Neumann J; Kirchner T; Jung A; Modest DP
Int J Cancer; 2016 Feb; 138(3):739-46. PubMed ID: 26284333
[TBL] [Abstract][Full Text] [Related]
3. Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.
Cascinu S; Georgoulias V; Kerr D; Maughan T; Labianca R; Ychou M
Ann Oncol; 2003; 14 Suppl 2():ii25-9. PubMed ID: 12810454
[TBL] [Abstract][Full Text] [Related]
4. Current treatments and future perspectives in colorectal and gastric cancer.
Wilke HJ; Van Cutsem E
Ann Oncol; 2003; 14 Suppl 2():ii49-55. PubMed ID: 12810459
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.
Folprecht G; Lutz MP; Schöffski P; Seufferlein T; Nolting A; Pollert P; Köhne CH
Ann Oncol; 2006 Mar; 17(3):450-6. PubMed ID: 16303861
[TBL] [Abstract][Full Text] [Related]
6. VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Thomaidis T; Maderer A; Al-Batran SE; Kany J; Pauligk C; Steinmetz K; Schad A; Hofheinz R; Schmalenberg H; Homann N; Galle PR; Moehler M
BMC Cancer; 2014 Jul; 14():476. PubMed ID: 24981311
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.
Ychou M; Hohenberger W; Thezenas S; Navarro M; Maurel J; Bokemeyer C; Shacham-Shmueli E; Rivera F; Kwok-Keung Choi C; Santoro A
Ann Oncol; 2009 Dec; 20(12):1964-70. PubMed ID: 19567451
[TBL] [Abstract][Full Text] [Related]
8. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
Bertagnolli MM; Niedzwiecki D; Compton CC; Hahn HP; Hall M; Damas B; Jewell SD; Mayer RJ; Goldberg RM; Saltz LB; Warren RS; Redston M
J Clin Oncol; 2009 Apr; 27(11):1814-21. PubMed ID: 19273709
[TBL] [Abstract][Full Text] [Related]
10. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
Graeven U; Arnold D; Reinacher-Schick A; Heuer T; Nusch A; Porschen R; Schmiegel W
Onkologie; 2007 Apr; 30(4):169-74. PubMed ID: 17396039
[TBL] [Abstract][Full Text] [Related]
11. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
12. [Systemic treatment of colorectal cancers--factual standards and perspectives].
Miron L
Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):752-8. PubMed ID: 14756014
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.
Papadimitriou CA; Papakostas P; Karina M; Malettou L; Dimopoulos MA; Pentheroudakis G; Samantas E; Bamias A; Miliaras D; Basdanis G; Xiros N; Klouvas G; Bafaloukos D; Kafiri G; Papaspirou I; Pectasides D; Karanikiotis C; Economopoulos T; Efstratiou I; Korantzis I; Pisanidis N; Makatsoris T; Matsiakou F; Aravantinos G; Kalofonos HP; Fountzilas G
BMC Med; 2011 Jan; 9():10. PubMed ID: 21281463
[TBL] [Abstract][Full Text] [Related]
14. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803.
Sargent D; Shi Q; Yothers G; Van Cutsem E; Cassidy J; Saltz L; Wolmark N; Bot B; Grothey A; Buyse M; de Gramont A;
Eur J Cancer; 2011 May; 47(7):990-6. PubMed ID: 21257306
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
16. [New therapeutic options in chemotherapy of advanced colorectal cancer].
Reimer P; Rückle-Lanz H
Med Klin (Munich); 2001 Oct; 96(10):593-8. PubMed ID: 11715331
[TBL] [Abstract][Full Text] [Related]
17. [Interferon-alpha in adjuvant treatment of colorectal carcinoma].
Staib L; Link KH; Henne-Bruns D
Kongressbd Dtsch Ges Chir Kongr; 2002; 119():142-5. PubMed ID: 12704877
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
Underhill C; Goldstein D; Gorbounova VA; Biakhov MY; Bazin IS; Granov DA; Hossain AM; Blatter J; Kaiser C; Ma D
Oncology; 2007; 73(1-2):9-20. PubMed ID: 18334829
[TBL] [Abstract][Full Text] [Related]
19. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?].
Carnaghi C; Zucali P; Garassino I
Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
